Acadia Healthcare said the derivative litigation settlement will deliver two headline financial outcomes: a $12 million monetary component and $4.75 million in attorneys’ fees and expenses, for a combined cash outlay of $16.75 million tied to the resolution.
The agreement follows more than three years of litigation and multiple mediation sessions. The timeline in the filing shows:
- The federal derivative action began on Feb. 21, 2019.
- The Pfenning action was filed on Oct. 23, 2020.
- The Solak action was filed on Feb. 24, 2021.
- The parties held an in-person mediation on Nov. 16, 2023.
- A second mediation was scheduled for May 14, 2025 but was canceled after the securities class action settlement talks stalled.
- A third mediation took place on Dec. 16, 2025.
- A mediator’s proposal for $12 million on the monetary component was accepted on Dec. 23, 2025.
- The corporate governance reforms were finalized on Jan. 13, 2026.
- The fee and expense amount of $4.75 million was agreed to on Feb. 25, 2026.
- The term sheet was executed on Mar. 3, 2026.
The underlying cases covered a broad span of allegations. The federal derivative action asserted claims under Sections 14(a) and 10(b) of the Exchange Act, along with fiduciary duty, waste, and unjust enrichment claims. The Delaware cases focused on fiduciary duty, waste, unjust enrichment, and insider trading allegations.
The filing also details the scope of the document production that fed the litigation:
- More than 800 pages of books-and-records materials were produced in response to both the Pfenning and Solak Section 220 demands.
- The Pfenning action later incorporated information from more than 4,800 pages of public records.
- The parties also exchanged securities-class-action document productions, including confidential documents and deposition transcripts, during the deferral periods.
The settlement caps plaintiffs’ counsel’s recovery at the $4.75 million fee-and-expense amount, and the company’s governance changes were negotiated alongside the cash payment. Following these announcements, the company's shares moved -2.49%, and are now trading at a price of $27.80. For more information, read the company's full 8-K submission here.
